leprosy (redirected from Leprosy-3 Virus)

leprosy or Hansen's disease (hăn`sənz), chronic, mildly infectious malady capable of producing, when untreated, various deformities and disfigurements. It is caused by the rod-shaped bacterium Mycobacterium leprae, first described by G. Armauer Hansen, a Norwegian physician, in 1874. The mode of transmission is not fully understood. It is thought to be transmitted by nasal discharges and skin sores, possibly also by contaminated objects and arthropods. Only 5% of those exposed acquire the disease. The onset is intermittent and gradual; symptoms may not appear until years after exposure. It is seldom fatal, but its involvement of the peripheral nerves destroys sensation and makes the patient prone to inadvertent injury.

Types of Leprosy

There are two forms of leprosy. In the tuberculoid form of the disease the skin lesions appear as light red or purplish spots. Tuberculoid leprosy is the more benign type, even though it is accompanied by nerve involvement, which leads to numbness (usually of the extremities), contractures, and ulceration. In lepromatous leprosy the skin lesions appear as yellow or brown infiltrated nodules (protuberances) that affect the mucous membranes of the eyes, nose, and throat. There is a general thickening of the skin, especially the face and ears. Lepromatous leprosy is the more easily spread of the two.

Diagnosis and Treatment

Diagnosis is established when the bacterium is isolated from the skin lesions or the mucous membranes of the nose. Duration and treatment of the disease depend upon its extent and character. Patients with nodular lesions are more difficult to treat and may succumb sooner; those with the neural type of lesion, despite possible mutilation and deformity, usually live longer and even experience spontaneous periods of subsidence of the malady. Dapsone was the drug of choice for leprosy from the 1940s until 1980, but due to drug resistance and the necessity for long-term (sometimes lifelong) treatment, it has been replaced by a combination of drugs. This combination, referred to as multiple drug therapy, has been highly effective and requires a shorter treatment period. The drug thalidomide has been approved for use against a complication of leprosy called erythema nodosum leprosum, which causes fever, skin lesions, and other symptoms.

History and Incidence

Diseases that probably included the malady now known as Hansen's disease are described as leprosy in the Bible; segregation and disinfection were advocated as methods of control (Lev. 13.14). Leprosy is believed to have existed in Egypt as long ago as 4000 B.C. and in India and Japan earlier than 1000 B.C. Infectious diseases from the East—all called leprosy—later spread over most of Europe and the British Isles, and the Crusades were a factor in disseminating them still farther, so that by the 13th cent. they had reached epidemic proportions. Leprosariums were eventually established in most countries for the care of those actually afflicted with leprosy.

The disease still occurs in tropical and subtropical countries of Asia, Africa, and Latin America—mainly Brazil, S central Africa, and India—especially where crowded and unsanitary conditions contribute to its spread. Even in the more developed countries it crops up from time to time. In the United States, the disease is found mostly in Louisiana, Texas, Florida, Hawaii, as well as in California, the Northeast, and other areas where immigrants from endemic areas have settled. Although modern treatment is effective against the disease, the number of cases in the United States has increased significantly since the 1960s. The World Health Organization is working to eradicate the disease worldwide, but progress has been more slow than was anticipated.

---

leprosy

 or Hansen disease

Chronic disease of the skin, peripheral nerves, and mucous membranes of the nose, throat, and eyes, caused by the bacterium Mycobacterium leprae. In tuberculoid leprosy, cells of the immune system crowd into infected areas of the skin, forming hard nodules, or tubercles, that spread along nerve fibres. This type of reaction commonly leads to claw hand, gross deformity of the foot, and paralysis of muscles of the face, eye, and neck. In the lepromatous type, bacilli multiply freely in deep layers of the skin and spread widely through lymphatic channels and along nerve fibres, causing thickening and corrugation of the skin, raising soft nodules on the ears, nose, and cheeks, and sometimes destroying the septum of the nose and the palate. Leprosy has a long history. Until the 20th century, infected people were ostracized from society or at best segregated and cared for in isolated leper colonies. Today the disease is entirely curable through multidrug therapy, though tissue damage caused before drug treatment cannot be reversed. Some 600,000 new cases arise every year, mostly in Asia, Africa, Central and South America, and the Pacific Islands. About 60 percent of new cases occur in India.

---

leprosy

Pathol a chronic infectious disease occurring mainly in tropical and subtropical regions, characterized by the formation of painful inflamed nodules beneath the skin and disfigurement and wasting of affected parts, caused by the bacillus Mycobacterium leprae

---

leprosy [′lep·rə·sē]

(medicine)

Hansen's disease

---

Leprosy

A chronic infectious disease caused by Mycobacterium leprae that primarily affects the skin and peripheral nerves and, to a lesser extent, the eyes and mucous membranes. Leprosy, or Hansen's disease, has been known for more than 2000 years. It afflicts at least 3 million people worldwide and is most common in developing countries. There are about 200 new cases yearly in the United States. Its epidemiology is not fully understood, but transmission probably takes place by the respiratory route. The bacillus is very slow-growing, and the incubation period is usually 3–5 years. Less than 5% of any population is susceptible, and these individuals have a deficient cell-mediated immune response specifically to M. leprae, which may be genetic in origin. Epidemics have occurred, but are rare. See Mycobacterial diseases

A skin rash and loss of feeling due to nerve damage by M. leprae are the hallmarks of leprosy. Usually the nerve damage is mild, but when severe the inability to feel, particularly in the hands and feet, predisposes the individuals to frequent injuries. Nerve involvement may also lead to a loss of muscle function that produces clawing of the fingers and toes as well as other neuromuscular dysfunctions. Manifestations of the disease depend upon the degree of the immune defect. Initially, most patients develop one or several depigmented areas of skin that may have decreased sensation, a stage referred to as indeterminate disease. The condition may self-heal. If treatment or self-healing does not halt the disease, it may progress to one of three advanced types. The mildest of these, tuberculoid disease, is usually manifested as a single large depigmented, scaly, numb area. The most severe type, lepromatous leprosy, usually involves most of the skin to varying degrees, with variously sized nodules or other changes. Between the two extremes immunologically is borderline disease, with skin changes of both types. The World Health Organization's simplified classification labels indeterminate and tuberculoid patients paucibacillary (few bacilli) and borderline and lepromatous patients multibacillary.

Paucibacillary disease is treated with dapsone plus rifampin for 6–12 months. Clofazimine is added for multibacillary individuals and the treatment continued for 2 or more years. Isolation is unnecessary, since patients become noninfectious within days of starting treatment. See Infectious disease